Medicine and Dentistry
Adenocarcinoma
16%
Analysis of Variance
16%
Biopsy
16%
Bosentan
16%
Cancer
75%
Cancer Mortality
16%
Carcinosarcoma
45%
Chronic Kidney Disease
100%
Clinical Feature
54%
Clinical Predictor
16%
Coronary Risk
16%
Diabetes Mellitus
16%
Disease
16%
End of Life Care
16%
Hemodialysis
50%
Hepatitis B Antibody
30%
Hepatitis B Vaccination
50%
Hepatocellular Carcinoma
50%
Hormone Substitution
50%
Hypophysitis
50%
Immune-Related Adverse Events
25%
Immunoglobulin A Nephropathy
50%
Immunohistochemistry
56%
Intracellular Signaling
16%
Leiomyosarcoma
69%
Log Rank Test
16%
Lung Calcification
50%
Lung Cancer
50%
Malignant Fibrous Histiocytoma
40%
Malignant Neoplasm
46%
Membrane Receptor
16%
Neoplasm
29%
Nodular Melanoma
50%
Observational Study
16%
Outpatient
16%
Pancreas Adenocarcinoma
56%
Pancreas Cancer
29%
Pancreas Carcinoma
50%
Patient Counseling
16%
Prevalence
72%
Primary Health Care
50%
Recombinant Hepatitis B Vaccine
20%
Renal Replacement Therapy
16%
Renal Tubular Acidosis
25%
Retrospective Study
23%
Sarcoma
50%
Soft Tissue Sarcoma
100%
Trastuzumab
31%
Vasculotropin
100%
Veterans Affairs
50%
Keyphrases
Acute Tumor Lysis Syndrome
25%
Age at Diagnosis
25%
Biopsy-proven
12%
Bone Marrow Iron
50%
Calcium Deposition
16%
Cancer Causes
17%
Cancer Mortality
17%
CD117
50%
Clinical Features
54%
Clinical Predictors
12%
Dermatofibrosarcoma
21%
Dialysis Facility
50%
Early Chronic Kidney Disease
12%
Hemodialysis
16%
Hemodialysis Initiation
16%
HER Family
25%
Histological Subtypes
15%
Hormone Replacement Therapy
50%
Hospice
50%
Hypophysitis
50%
Immune-related Adverse Events
25%
Incidence Rate
12%
Leiomyosarcoma
55%
Lessons Learned
50%
Living Donor Evaluation
50%
Lung Cancer
50%
Malignant Fibrous Histiocytoma
15%
Metastatic Calcification
50%
Mortality Rate
12%
Nephrotoxic Effect
25%
Older Patients
12%
Overexpression
50%
Pancreatic Adenocarcinoma
50%
Pre-dialysis Patients
12%
Predictive Value
50%
Protective Antibody Levels
12%
Rank Analysis
12%
Renal Adverse Effects
25%
Renal Tubular Acidosis
25%
Retrospective Observational Study
18%
Single-center Experience
50%
Smoking History
30%
Soft Tissue Sarcoma
50%
Statistical Analysis
12%
Survival Prediction
12%
Type 1 Diabetes Mellitus (T1DM)
12%
Vascular Endothelial Growth Factor
50%
Vascular Endothelial Growth Factor Expression
15%
Vascular Endothelial Growth Factor Receptor Inhibitor
25%
Veterans Affairs
50%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
50%
Adverse Event
25%
Aflibercept
50%
Bevacizumab
25%
Bosentan
16%
Cetuximab
50%
Chronic Kidney Failure
75%
Coronary Risk
16%
Cytotoxic Agent
25%
Dasatinib
25%
Electrolyte Disturbance
25%
Epidermal Growth Factor Receptor
25%
Everolimus
25%
Gamma Urogastrone
25%
Hypokalemia
25%
Hypomagnesemia
25%
Hypophysitis
50%
Imatinib
25%
Ipilimumab
50%
Kidney Disease
25%
Kidney Infection
8%
Kidney Tubule Acidosis
25%
Leiomyosarcoma
7%
Lung Cancer
50%
Malignant Fibrous Histiocytoma
7%
Malignant Neoplasm
73%
Mammalian Target of Rapamycin Inhibitor
25%
Monoclonal Antibody
50%
Nephrotoxicity
50%
Overall Survival
9%
Panitumumab
25%
Protein Tyrosine Kinase
25%
Protein Tyrosine Kinase Inhibitor
50%
Proteinuria
50%
Replacement Therapy
50%
Rituximab
50%
Side Effect
25%
Trastuzumab
6%
Tumor Lysis Syndrome
25%
Vasculotropin
25%
Vasculotropin Receptor
25%
